Samsung Electronics Shares Jump on HBM4 Mass Production Report 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
SOUTH SAN FRANCISCO, Calif., Jan. 21, 2016 -- Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials addressing multi-drug resistant (MDR) gram-negative infections, announced today that it has joined over 80 pharmaceutical, biotechnology, and diagnostics companies in drafting and signing the Declaration on Combating Antimicrobial Resistance. The Declaration – which highlights the continued increase of bacterial resistance to antibiotics and the urgent need to develop new, innovative drugs – is a call to action, outlining specific initiatives that governments and industry can implement in a collaborative effort to further address the threat of Antimicrobial Resistance (AMR). This initiative further demonstrates Achaogen’s commitment to economic, regulatory, and reimbursement reform toward establishing a sustainable solution that incentivizes the development and commercialization of novel antibiotics addressing the unmet need of treating drug resistant infections.
“Achaogen is focused on the discovery and development of new antibacterials to treat multi-drug resistant, gram-negative infections and is committed to participating in the coordinated global action required to address the public health threat posed by AMR,” said Kenneth Hillan, Achaogen’s Chief Executive Officer. “We applaud the efforts of Lord O’Neill’s Review on AMR and are pleased to support this Declaration and the call for collective global measures to overcome the barriers to the development and commercialization of life-saving antibiotics.”
The Declaration, along with a complete list of signatories, is available at the Review on AMR website at www.amr-review.org/industry-declaration.
About Achaogen
Achaogen is a clinical-stage biopharmaceutical company passionately committed to the discovery, development, and commercialization of novel antibacterials to treat MDR gram-negative infections. Achaogen is developing plazomicin, Achaogen’s lead product candidate, for the treatment of serious urinary tract, lung, and bloodstream infections due to Enterobacteriaceae, including CRE. Achaogen’s plazomicin program is funded in part with a contract from the Biomedical Advanced Research and Development Authority. Plazomicin is the first clinical candidate from Achaogen’s gram-negative antibiotic discovery engine, and Achaogen has other programs in early and late preclinical stages focused on other MDR gram-negative infections. For more information, please visit www.achaogen.com.
Contact Candice Knoll Blueprint Life Science Group 415.375.3340 Ext. 4 [email protected]
